SILEXION THERAPEUTICS CORP (SLXN)
Common Stock
Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors
Prof. Peled, a globally recognized scientific authority who has been involved in multiple successful publicly traded bio-pharma companies, will assist...
Silexion Therapeutics Announces 1-for-9 Reverse Share Split
Trading on split-adjusted basis will begin at market open on November 29, 2024. This adjustment is expected to help Silexion comply with NASDAQ...
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA...
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage,...
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024...